Design, recruitment and baseline characteristics of the LENS trial.

ABSTRACT:

Background

Findings from cardiovascular outcome trials suggest that treatment with fenofibrate may reduce the progression of diabetic retinopathy. However, no dedicated large-scale randomised trials have yet investigated this hypothesis.

Methods

LENS is a streamlined randomised double-masked placebo-controlled trial, based in Scotland, assessing whether treatment with fenofibrate (145 mg tablet daily or, in the context of impaired renal function, on alternate days) in people with early retinopathy reduces progression to referable diabetic retinopathy (defined in NHS Scotland's Diabetic Eye Screening grading scheme as referable background or proliferative retinopathy, or referable maculopathy in either eye) or treatment with retinal laser, intravitreal injections or vitrectom

SUBMITTER: LENS Collaborative Group 

PROVIDER: S-EPMC7617915 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature